Sign In
Buy STTK
$4.75
-0.120 (-2.46%)
At Close: Jun 03, 2026
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
06:15am, Thursday, 07'th May 2026
AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of pote
Aberdeen Group plc Buys 436,673 Shares of Shattuck Labs, Inc. $STTK
03:08am, Friday, 10'th Apr 2026
Aberdeen Group plc increased its stake in Shattuck Labs, Inc. (NASDAQ: STTK) by 462.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 531,177 shar
Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $10.50
01:09am, Monday, 06'th Apr 2026
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat.com reports.
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
04:42pm, Friday, 06'th Mar 2026
The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
06:15am, Thursday, 05'th Mar 2026
AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of po
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
08:00am, Wednesday, 25'th Feb 2026
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-cl
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $6.20 Consensus PT from Analysts
04:08am, Sunday, 08'th Feb 2026
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has earned a consensus rating of "Hold" from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities researc
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
08:30am, Friday, 06'th Feb 2026
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targ
Shattuck Labs, Inc. (NASDAQ:STTK) Sees Large Growth in Short Interest
02:54am, Sunday, 01'st Feb 2026
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 2,198,677 shares, an increas
Why Shattuck Labs Stock Soared in December
10:30pm, Monday, 05'th Jan 2026
An analyst's recommendation upgrade had a major impact on investor sentiment. It's now a buy, according to the pundit.
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 15'th Dec 2025
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy
04:33pm, Monday, 01'st Dec 2025
HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company's lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory b
Shattuck Labs to Participate in Upcoming December Investor Conferences
08:00am, Thursday, 20'th Nov 2025
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
04:30pm, Thursday, 06'th Nov 2025
–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – A
Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript
09:16pm, Friday, 10'th Oct 2025
Shattuck Labs, Inc. (NASDAQ:STTK ) The United European Gastroenterology (UEG) Congress UEG Week 2025 October 8, 2025 10:00 AM EDT Company Participants Taylor Schreiber - Co-Founder, CEO & Director Con
